Additive study design | Substitutive study design | Orphan drug with competition | Orphan drug soloist | |||
---|---|---|---|---|---|---|
Added benefit not proven | Added benefit proven palliative ACT (BSC) | Added benefit proven curative ACT | Added benefit not proven | Added benefit proven | Added benefit proven by law | |
Pertuzumab 1. Ind 2. SG Regorafenib new EBA Pertuzumab 2. Ind | Cabazitaxel 1. SG Ipilimumab 1. Ind Abiraterone 1. Ind Vandetanib new EBA Enzalutamid 1. Ind Regorafenib 1. Ind Radium-223- dichloride 2. SG Ruxolitinib new EBA | Aflibercept Pertuzumab 1. SG Nintedanib | Dabrafenib | Eribulin 1. SG Vemurafenib Axitinib 2. SG Crizotinib 1. SG Vemurafenib new EBA Afatinib 1. SG Trastuzumab 2. SG Ruxolitinib Afatinib new EBA Nivolumab 2. SG Pembrolizumab 2./3. SG Trametinib Abiraterone 2. Ind Eribulin 2. Ind Enzalutamide 2. Ind | Decitabin Bosutinib Ponatinib Cabozantinib Obinutuzumab Ibrutinib Lenvatinib | Ruxolitinib Brentuximab Vedotin Ramucirumab Olaparib |